← Back to Clinical Trials
Recruiting Phase 2, Phase 3 NCT06872736

NCT06872736 Wereables for Upper Limb Functionality in Hemiparesis

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06872736
Status Recruiting
Phase Phase 2, Phase 3
Sponsor Universidade da Coruña
Condition Unilateral Cerebral Palsy
Study Type INTERVENTIONAL
Enrollment 40 participants
Start Date 2024-06-07
Primary Completion 2024-09-14

Eligibility & Interventions

Sex All sexes
Min Age 3 Years
Max Age 8 Years
Study Type INTERVENTIONAL
Interventions
WeFun-wearable activatedWeFun-wearable desactivated

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.

This trial targets 40 participants in total. It began in 2024-06-07 with a primary completion date of 2024-09-14.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The project is configured as a national interventional study that aims to determine the effectiveness of an intervention strategy using wearable technology, tailored to improve function (WeFun-wearable), on the spontaneous use of the affected upper extremity, activities of daily living and the participation in children with unilateral cerebral palsy.

Eligibility Criteria

Inclusion Criteria: * Confirmed diagnosis of UCP. * Children aged between 3 and 8 years old. * Children rated on levels I to III on the Manual Ability Classification System (MACS). Exclusion Criteria: * Botulinum toxin injection or surgical interventions in the upper limb within 6 months prior to study entry. * Medical complications non-controlled that would interfere with study participation (e.g., not controlled epilepsy). * Predominantly athetoid or dystonia movement patterns. * Insufficient cognitive level to follow instructions, * Non-corrected marked visual impairments. Families can be retired from the study after starting if: * Families don't assist or don't collaborate in the weekly sessions with the reference person. * Wearable activity if presumably lower than expected (few recordings of activity, \<20%). * Families don't provide feedback about daily sessions through the satisfaction system in the app/registration sheet.

Contact & Investigator

Central Contact

Verónica Robles García, PhD

✉ veronica.robles@udc.es

📞 +34 981167000

Frequently Asked Questions

Who can join the NCT06872736 clinical trial?

This trial is open to participants of all sexes, aged 3 Years or older, up to 8 Years, studying Unilateral Cerebral Palsy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

What phase is the NCT06872736 trial and what does that mean for participants?

Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.

Is NCT06872736 currently recruiting?

Yes, NCT06872736 is actively recruiting participants. Contact the research team at veronica.robles@udc.es for enrollment information.

Where is the NCT06872736 trial being conducted?

This trial is being conducted at A Coruña, Spain.

Who is sponsoring the NCT06872736 clinical trial?

NCT06872736 is sponsored by Universidade da Coruña. The trial plans to enroll 40 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology